FDA Requests More Information Before Approving Lung Drug for Infants
Drug manufacturer AstraZeneca PLC will reportedly have to provide the Food and Drug (FDA) Administration with more information about their new lung drug for infants before the agency will grant permission for it to be released onto the market. As reported by the Associated Press (AP), the company announced on Friday that the FDA requested more information about Motavizumab, which was developed for the prevention of lung infections in babies.
AstraZeneca spokesperson Sarah Lindgreen was quoted as stating “We’re not yet speculating on what impact it will have on a possible launch date.” However, there is a possibility that the company will not be able to meet their original release date goal in 2009 due to complying with the request.
As noted in the report, AstraZeneca currently has another respiratory virus treatment on the market, Synergis, which analysts list as one reason the possible delay may not significantly impact the company’s sales.
Tags: AstraZeneca, Drug, FDA, lung, manufacturer, Motavizumab, SynergisOnline Health & Fitness News Press Release Distribution - WiredPRNews.com
- FREE Local Childhood Obesity Prevention Program Changes Kids Lives
- New Classification System for Air Filters Homes in on Efficiency, Savings
- Soprano Laser Hair Removal Now More Effective then IPL
- ‘New Year, New You’ Already in Jeopardy, As Brits Quit The Gym!
- Sustainability in the Workplace: Healthier Air, Higher Morale
- High Dose Rate Electronic Radiation Skin Cancer Treatment Now Available in US
- Chicago’s Gold Coast Goes Green As Skin Care Line Opens Flagship Sales Office
- Free Exercise Manual Aims to Reduce Childhood Obesity
- No Texting While Paddling: SUP Eco Adventures Provides THE Alternative
- Sandusky Accusers Get Foundation’s Help
